PO.TB10.07 · 肿瘤生物学

利用高分辨率空间转录组学提升bulk测序价值:CRC与NSCLC中临床相关空间生态位的配对数据分析

Elevating bulk sequencing with high-resolution spatial transcriptomics: A paired-data analysis of clinically-relevant spatial niches in CRC and NSCLC

编号 6187 展板 1 时间 4/21 02:00–05:00 区域 Section 31 主讲 Yajas Shah
分会场 Spatial Niches and Functional Boundaries within the Tumor Microenvironment 2
该海报暂无可下载的资料 AACR 官方页面

作者与单位 Authors & Affiliations

Yajas Shah, Tianyou Luo, Christine M. Hoeman, Luca Lonini, Stanislaw Szydlo, Eduardo Diaz, Rossin Erbe, Matthew B. Maxwell, Michelle M. Stein, Andrew J. Sedgewick, Nicholas Rachell, Zachary Chelsky, Sonal Khare, Ryan D. Jones, Kate Sasser, Richard A. Klinghoffer, Justin Guinney, Chi-Sing Ho

Tempus AI, Chicago, IL

摘要 Abstract

中文摘要
背景。Bulk RNA二代测序(RNA-NGS)是实体瘤分子表征的标准工具,并在临床实践中用于指导治疗选择。然而,肿瘤微环境的空间组织(在bulk RNA-NGS中无法观测)在临床表型和治疗反应中发挥着重要作用。虽然空间转录组学(ST)克服了bulk测序的局限,但在真实世界癌症患者中,ST、bulk NGS与临床表型三者之间的关系尚未被探索。为此,我们生成并分析了一个大型多模态真实世界队列,其中包含结直肠癌(CRC)和非小细胞肺癌(NSCLC)肿瘤,均对来自同一生物样本的ST、bulk RNA-NGS和靶向DNA-NGS数据进行了分析。 方法。使用10X Genomics Visium HD平台,在全转录组水平上生成了来自42例NSCLC(16例转移性)和19例CRC(6例肺转移和6例肝转移)患者、共370万个细胞的基因表达数据。使用scVI对细胞进行整合,使用SCimilarity进行注释。使用CellCharter生成空间信息聚类。使用线性模型对空间、临床和生物标志物特征(包括Tempus免疫图谱评分[IPS])之间进行关联检验,并酌情对临床特征(肿瘤类型、分期、组织学、转移)和分子特征(TMB)进行校正。 结果。Visium HD的伪bulk与配对的bulk RNA显示出高度相关性,Spearman相关系数中位数为0.79(IQR:0.78-0.81)。基因表达的空间聚类揭示了六个不同的空间生态位:两个富集上皮细胞,一个富集基质细胞,三个富集免疫细胞(髓系富集区、淋巴系富集区和肿瘤-免疫混合区)。在源自肺部的NSCLC肿瘤中,我们发现髓系、淋巴系和基质富集生态位分别富集于I期、II期和IV期病例(p < 0.05)。空间生态位与NSCLC(淋巴系、髓系和基质富集,CDKN2A、KEAP1、RBM10,p < 0.05)和CRC(淋巴系和髓系富集,KRAS、TP53,p < 0.05)中的关键致癌改变相关。IPS评分较高的患者与淋巴系和肿瘤-免疫混合生态位的富集相关(p < 0.05),而来自肿瘤-免疫混合区的细胞比淋巴细胞富集区表达更高水平的免疫浸润和耗竭标志物(IKZF2、TOX2、PTPRC、CD69)。 结论。我们的工作刻画了导致空间异质性的基因组和转录特征,揭示了与免疫细胞浸润相关的不同分子模式。该数据集为理解肿瘤微环境驱动的表型、将纯空间学洞见转化为可扩展的生物标志物提供了强大的基础,助力未来精准肿瘤学的转化发现。
查看英文原文 English abstract
Background. Bulk RNA-next generation sequencing (RNA-NGS) is a standard tool for the molecular characterization of solid tumors and is used in clinical practice to guide therapy selection. However, the spatial organization of the tumor microenvironment (unobservable in bulk RNA-NGS) plays an important role in clinical phenotypes and therapy response. While spatial transcriptomics (ST) overcomes the limitations of bulk sequencing, the relationship amongst ST, bulk NGS, and clinical phenotypes in real-world cancer patients has not been explored. To address this, we generated and analyzed a large multimodal, real-world cohort of colorectal (CRC) and non-small cell lung cancer (NSCLC) tumors profiled with ST, bulk RNA-NGS and targeted DNA-NGS data from the same biospecimen. Methods. Gene expression data from 3.7 million cells, sourced from 42 NSCLC (16 metastatic) and 19 CRC (6 lung and 6 liver metastases) patients were generated at whole-transcriptome level using 10X Genomics Visium HD platform. Cells were integrated using scVI and annotated using SCimilarity. Spatially-informed clusters were generated using CellCharter. Association testing between spatial, clinical, and biomarker features, including the Tempus Immune Profile Score (IPS) were performed using linear models adjusted for clinical (tumor type, stage, histology, metastasis) and molecular features (TMB) as appropriate. Results. Visium HD pseudo-bulk showed high correlation with paired bulk RNA, with a median Spearman correlation of 0.79 (IQR: 0.78-0.81). Spatial clustering of gene expression revealed six distinct spatial niches: two enriched for epithelial cells, one for stromal cells, and three for immune cells (myeloid-rich, lymphoid-rich, and tumor-immune mixed regions). Among NSCLC tumors sourced from the lung, we found that the myeloid, lymphoid and stroma-rich niches were enriched for Stage I, II and IV cases respectively (p < 0.05). Spatial niches were associated with key oncogenic alterations in NSCLC (lymphoid-, myeloid- and stroma-rich, CDKN2A , KEAP1 , RBM10 , p < 0.05) and CRC (lymphoid- and myeloid-rich, KRAS , TP53 , p < 0.05). Patients with higher IPS scores were associated with an enrichment of lymphoid and tumor-immune mixed niches (p < 0.05), while cells from tumor-immune mixed regions had higher expression of immune infiltration and exhaustion markers than the lymphocyte-rich regions ( IKZF2 , TOX2 , PTPRC , CD69 ). Conclusion. Our work profiles the genomic and transcriptional features contributing to spatial heterogeneity, revealing distinct molecular patterns associated with immune cell infiltration. This dataset provides a powerful foundation for understanding tumor microenvironment-driven phenotypes and translating spatial-only insights into scalable biomarkers, empowering future translational discovery in precision oncology.
利益披露 Disclosure
Y. Shah, Tempus AI Employment, Stock. T. Luo, Tempus AI Employment, Stock, Patent. C. M. Hoeman, Tempus AI Employment. L. Lonini, Tempus AI Employment, Stock, Patent. S. Szydlo, Tempus AI Employment, Stock. E. Diaz, Tempus Employment. R. Erbe, Tempus AI Employment, Stock. M. B. Maxwell, Tempus AI Employment. M. M. Stein, Tempus AI Employment, Stock. A. J. Sedgewick, Tempus AI Employment, Stock. N. Rachell, Tempus AI Employment. Z. Chelsky, Tempus AI Employment, Stock. S. Khare, Sonal Khare Employment, Stock. R. D. Jones, Tempus AI Employment, Stock, Patent. K. Sasser, Tempus AI Employment, Stock. R. A. Klinghoffer, Tempus AI Employment, Stock. Presage Biosciences Employment, Stock, Stock Option. J. Guinney, Tempus AI Employment, Stock, Patent. C. Ho, Tempus AI Employment, Stock, Patent.

← 返回 AACR 2026 检索